Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution
Menu

Contact Us
If you have any questions or feedback please contact us.

Kavita Venugcpal Nair

TitleProfessor
InstitutionUniversity of Colorado Denver - Anschutz Medical Campus
DepartmentSOP-Administration
Phone303/724-2635

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. de Havenon A, Delic A, Dehoney S, Whetman P, Sheibani N, Callaghan B, Ney J, Esper GJ, Magliocco B, Nair KV. Five-Year Trends in Payments for Neurologist-Prescribed Drugs in Medicare Part D. Neurology. 2021 04 20; 96(16):e2132-e2137. PMID: 33692164.
      View in: PubMed
    2. Vollmer TL, Cohen JA, Alvarez E, Nair KV, Boster A, Katz J, Pardo G, Pei J, Raut P, Merchant S, MacLean E, Pradhan A, Moss B. Safety results of administering ocrelizumab per a shorter infusion protocol in patients with primary progressive and relapsing multiple sclerosis. Mult Scler Relat Disord. 2020 Nov; 46:102454. PMID: 33045496.
      View in: PubMed
    3. Vollmer BL, Nair K, Sillau S, Corboy JR, Vollmer T, Alvarez E. Rituximab versus natalizumab, fingolimod, and dimethyl fumarate in multiple sclerosis treatment. Ann Clin Transl Neurol. 2020 09; 7(9):1466-1476. PMID: 32767538.
      View in: PubMed
    4. Nair KV, Wolfe P, Valuck RJ, McCollum MM, Ganther JM, Lewis SJ. Effects of a 3-Tier Pharmacy Benefit Design on the Prescription Purchasing Behavior of Individuals With Chronic Disease. J Manag Care Spec Pharm. 2020 May; 26(5):575-585. PMID: 32347176.
      View in: PubMed
    5. Vollmer B, Ontaneda D, Harris H, Nair K, Bermel RA, Corboy JR, Fox RJ, Vollmer T, Cohen JA, Alvarez E, Hersh CM. Comparative discontinuation, effectiveness, and switching practices of dimethyl fumarate and fingolimod at 36-month follow-up. J Neurol Sci. 2019 Dec 15; 407:116498. PMID: 31644992.
      View in: PubMed
    6. Weinkle L, Domen CH, Shelton I, Sillau S, Nair K, Alvarez E. Exploring cannabis use by patients with multiple sclerosis in a state where cannabis is legal. Mult Scler Relat Disord. 2019 Jan; 27:383-390. PMID: 30502644.
      View in: PubMed
    7. Vollmer B, Ontaneda D, Bandyopadhyay A, Cohn S, Nair K, Sillau S, Bermel RA, Corboy JR, Fox RJ, Vollmer T, Cohen JA, Alvarez E, Hersh CM. Discontinuation and comparative effectiveness of dimethyl fumarate and fingolimod in 2 centers. Neurol Clin Pract. 2018 Aug; 8(4):292-301. PMID: 30140580.
      View in: PubMed
    8. Vollmer B, Honce JM, Sillau S, Corboy JR, Vollmer T, Nair K, Alvarez E. The impact of very short transition times on switching from Natalizumab to Fingolimod on imaging and clinical effectiveness outcomes in multiple sclerosis. J Neurol Sci. 2018 07 15; 390:89-93. PMID: 29801915.
      View in: PubMed
    9. Dilokthornsakul P, Valuck RJ, Nair KV, Corboy JR, Allen RR, Campbell JD. Multiple sclerosis prevalence in the United States commercially insured population. Neurology. 2016 Mar 15; 86(11):1014-21. PMID: 26888980.
      View in: PubMed
    10. McQueen RB, Livingston T, Vollmer T, Corboy J, Buckley B, Allen RR, Nair K, Campbell JD. Increased relapse activity for multiple sclerosis natalizumab users who become nonpersistent: a retrospective study. J Manag Care Spec Pharm. 2015 Mar; 21(3):210-8b. PMID: 25726030.
      View in: PubMed
    11. McQueen RB, Ellis SL, Maahs DM, Anderson HD, Nair KV, Libby AM, Campbell JD. Association between glycated hemoglobin and health utility for Type 1 diabetes. Patient. 2014; 7(2):197-205. PMID: 24458545.
      View in: PubMed
    12. Campbell JD, Ghushchyan V, Brett McQueen R, Cahoon-Metzger S, Livingston T, Vollmer T, Corboy J, Miravalle A, Schreiner T, Porter V, Nair K. Burden of multiple sclerosis on direct, indirect costs and quality of life: National US estimates. Mult Scler Relat Disord. 2014 Mar; 3(2):227-36. PMID: 25878010.
      View in: PubMed
    13. Campbell JD, McQueen RB, Miravalle A, Corboy JR, Vollmer TL, Nair K. Comparative effectiveness of early natalizumab treatment in JC virus-negative relapsing-remitting multiple sclerosis. Am J Manag Care. 2013 Apr; 19(4):278-85. PMID: 23725360.
      View in: PubMed
    14. Libby AM, Fish DN, Hosokawa PW, Linnebur SA, Metz KR, Nair KV, Saseen JJ, Vande Griend JP, Vu SP, Hirsch JD. Patient-level medication regimen complexity across populations with chronic disease. Clin Ther. 2013 Apr; 35(4):385-398.e1. PMID: 23541707.
      View in: PubMed
    15. Nair KV, Naim AB, Draaghtel K, Van Den Bos J. Work absences and expenditures for employees with autoimmune inflammatory diseases. J Occup Environ Med. 2012 Oct; 54(10):1268-74. PMID: 22995815.
      View in: PubMed
    16. Saseen JJ, Agashivala N, Allen RR, Ghushchyan V, Yadao AM, Nair KV. Comparison of patient characteristics and gout-related health-care resource utilization and costs in patients with frequent versus infrequent gouty arthritis attacks. Rheumatology (Oxford). 2012 Nov; 51(11):2004-12. PMID: 22829689.
      View in: PubMed
    17. Nair K, Ghushchyan V, Van Den Bos J, Halford ML, Tan G, Frech-Tamas FH, Doyle J. Burden of illness for an employed population with chronic obstructive pulmonary disease. Popul Health Manag. 2012 Oct; 15(5):267-75. PMID: 22401150.
      View in: PubMed
    18. Abbott ZI, Nair KV, Allen RR, Akuthota VR. Utilization characteristics of spinal interventions. Spine J. 2012 Jan; 12(1):35-43. PMID: 22138113.
      View in: PubMed
    19. McQueen RB, Ellis SL, Campbell JD, Nair KV, Sullivan PW. Cost-effectiveness of continuous glucose monitoring and intensive insulin therapy for type 1 diabetes. Cost Eff Resour Alloc. 2011 Sep 14; 9:13. PMID: 21917132.
      View in: PubMed
    20. Nair KV, Corboy J, Kahler K, Allen RR, Ghushcyan V, McQueen RB, Bainbridge J, Dastani H, Mody-Patel N. Use of diagnostic tests and procedures for disease-modifying therapy users and non-disease-modifying therapy users with multiple sclerosis. Expert Rev Neurother. 2011 Jun; 11(6):787-98. PMID: 21651327.
      View in: PubMed
    21. Nair KV, Frech-Tamas F, Jan S, Wolfe P, Allen RR, Saseen JJ. Comparing pre-gap and gap behaviors for Medicare beneficiaries in a Medicare managed care plan. J Health Care Finance. 2011; 38(2):38-53. PMID: 22372031.
      View in: PubMed
    22. Nair KV, Miller K, Park J, Allen RR, Saseen JJ, Biddle V. Prescription co-pay reduction program for diabetic employees. Popul Health Manag. 2010 Oct; 13(5):235-45. PMID: 20879904.
      View in: PubMed
    23. Bhardwaja B, Carroll N, Korner E, Nair KV. Impact of prescription benefit coverage limits on sevelamer hydrochloride adherence for patients with ESRD. Am Health Drug Benefits. 2009 Sep; 2(6):242-50. PMID: 25126297.
      View in: PubMed
    24. Nair KV, Park J, Wolfe P, Saseen JJ, Allen RR, Ganguly R. Consumer-driven health plans: impact on utilization and expenditures for chronic disease sufferers. J Occup Environ Med. 2009 May; 51(5):594-603. PMID: 19369897.
      View in: PubMed
    25. Nair KV, Tang B, Van Den Bos J, Zhang V, Saseen JJ, Naim A, Rahman M. Categorization of infliximab dose changes and healthcare utilization and expenditures for patients with rheumatoid arthritis in commercially insured and Medicare-eligible populations. Curr Med Res Opin. 2009 Feb; 25(2):303-14. PMID: 19192975.
      View in: PubMed
    26. Nair KV, Miller K, Saseen J, Wolfe P, Allen RR, Park J. Prescription copay reduction program for diabetic employees: impact on medication compliance and healthcare costs and utilization. Am Health Drug Benefits. 2009 Jan; 2(1):14-24. PMID: 25126268.
      View in: PubMed
    27. Nair KV, Saseen JJ. Quality assessment of dyslipidemia in managed care: current best evidence should be used to benchmark quality. Ann Pharmacother. 2006 Jan; 40(1):124-7. PMID: 16368926.
      View in: PubMed
    28. Sullivan PW, Nair KV, Patel BV. The effect of the Rx-to-OTC switch of loratadine and changes in prescription drug benefits on utilization and cost of therapy. Am J Manag Care. 2005 Jun; 11(6):374-82. PMID: 15974556.
      View in: PubMed
    29. Nair KV, Sullivan PW. Therapeutic and economic consequences of OTC loratadine. Ann Pharmacother. 2004 Jan; 38(1):169-71. PMID: 14742815.
      View in: PubMed
    30. Valuck RJ, Williams SA, MacArthur M, Saseen JJ, Nair KV, McCollum M, Ensor JE. A retrospective cohort study of correlates of response to pharmacologic therapy for hyperlipidemia in members of a managed care organization. Clin Ther. 2003 Nov; 25(11):2936-57. PMID: 14693317.
      View in: PubMed
    31. Nair KV. Do consumers' attitudes predict prescription purchasing behavior? Manag Care Interface. 2003 Jun; 16(6):22-7, 55. PMID: 12841073.
      View in: PubMed
    32. Nair KV, Wolfe P, Valuck RJ, McCollum MM, Ganther JM, Lewis SJ. Effects of a 3-tier pharmacy benefit design on the prescription purchasing behavior of individuals with chronic disease. J Manag Care Pharm. 2003 Mar-Apr; 9(2):123-33. PMID: 14613341.
      View in: PubMed
    33. Nair KV, Ganther JM, Valuck RJ, McCollum MM, Lewis SJ. Impact of multi-tiered pharmacy benefits on attitudes of plan members with chronic disease states. J Manag Care Pharm. 2002 Nov-Dec; 8(6):477-91. PMID: 14613381.
      View in: PubMed
    34. Nair KV. Evaluation of health and pharmacy benefit information in health plan information packages. Manag Care Interface. 2001 Dec; 14(12):51-4. PMID: 11794843.
      View in: PubMed
    Nair's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    See all (166) concept(s)
    _
    Co-Authors Expand Description
    See all (16) people
    _
    Similar People Expand Description
    See all (60) people
    _
    Same Department Expand Description
    Search Department

    Copyright © 2021 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)